<?xml version="1.0" encoding="UTF-8"?>
<Bundle xmi:version="2.0" xmlns:xmi="http://www.omg.org/XMI" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  >
  <type value="collection"/>
  <entry>
    <resource>
      <PlanDefinition>
        <identifier>
          <value value="465b92c8-4864-5ef0-bd28-3997ce96c134"/>
          <assigner>
            <display value="urn:va.gov:kbs:knart:artifact:r1"/>
          </assigner>
        </identifier>
        <identifier>
          <value value="CLIN0008DA"/>
          <assigner>
            <display value="urn:va.gov:kbs:contract:VA118-16-D-1008:to:VA-118-16-F-1008-0007"/>
          </assigner>
        </identifier>
        <identifier>
          <value value="KP-886"/>
          <assigner>
            <display value="urn:cognitivemedicine.com:lab:jira"/>
          </assigner>
        </identifier>
        <name value="Cardiology: Inpatient Heparin Anticoagulation Protocol Order Set"/>
        <title value="Cardiology: Inpatient Heparin Anticoagulation Protocol Order Set"/>
        <type>
          <coding>
            <code value="Order Set"/>
          </coding>
        </type>
        <status value="active"/>
        <description/>
        <useContext>
          <code>
            <code value="TargetUser"/>
            <display value="Hospitalists, Residents and other ordering providers involved in managing the patient cohort"/>
          </code>
        </useContext>
        <useContext>
          <code>
            <code value="PatientAgeGroup"/>
            <display value="Adult patients"/>
          </code>
          <valueCodeableConcept>
            <coding>
              <system  value="SNOMED CT"/>
              <code value="133936004 "/>
              <display  value="Adult (person)"/>
            </coding>
          </valueCodeableConcept>
        </useContext>
        <useContext>
          <code>
            <code value="ClinicalFocus"/>
            <display value="Routine"/>
          </code>
          <valueCodeableConcept>
            <coding>
              <system  value="SNOMED CT"/>
              <code value="50811001 "/>
              <display  value="Routine (qualifier value)"/>
            </coding>
          </valueCodeableConcept>
        </useContext>
        <useContext>
          <code>
            <code value="ClinicalVenue"/>
            <display value="Inpatient"/>
          </code>
        </useContext>
        <useContext>
          <code>
            <code value="WorkflowSetting"/>
            <display value="Surgical and Medical Service"/>
          </code>
        </useContext>
        <useContext>
          <code>
            <code value="WorkflowTask"/>
            <display value="Adult inpatients requiring therapeutic anticoagulation management"/>
          </code>
        </useContext>
        <action>
          <action>
            <title value="Medications"/>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="Acute DVT of Leg Treated with Vitamin K Antagonist"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                            dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux,                             subcutaneous unfractionated heparin,                            intravenous heparin.                            These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg."/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg."/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg."/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg."/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg."/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg."/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg."/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion:"/>
                  <action>
                    <title value="Select one or both."/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now."/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now."/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol:                                               If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.                                               If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                               If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol:                                               If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.                                               If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                               If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="High Clinical Suspicion of Acute VTE"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux,                             subcutaneous unfractionated heparin,                            intravenous heparin.                            These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg."/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg."/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg."/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg."/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg."/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion:"/>
                  <action>
                    <title value="Select one or both."/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol:                                               If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change"/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol:                                               If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="Intermediate Clinical Suspicion of Acute VTE and Results of Diagnostic Tests Expect to Be Delayed > 4 Hours"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux,subcutaneous unfractionated heparin,intravenous heparin. These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg."/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg."/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg."/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg."/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg."/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion:"/>
                  <action>
                    <title value="Select one or both."/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="Acute Isolated Distal DVT of Leg and Severe Symptoms or Risk Factors for Extension"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux, subcutaneous unfractionated heparin, intravenous heparin. These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
                  <action>
                    <title value="Select one or both"/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="Acute Isolated Distal DVT of Leg if Thrombus Extends within Distal System or into Proximal Veins"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux,                             subcutaneous unfractionated heparin,                            intravenous heparin.                            These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
                  <action>
                    <title value="Select one or both."/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now."/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now."/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="Acute Deep Vein Thrombosis of Leg with Thrombosis Removal"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux,                             subcutaneous unfractionated heparin,                            intravenous heparin.                            These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion:"/>
                  <action>
                    <title value="Select one or both."/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.                                               If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.                                               If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="Acute Proximal Deep Vein Thrombosis of Leg and Inferior Vena Cava Filter if Risk of Bleeding Resolves"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux,                             subcutaneous unfractionated heparin,                            intravenous heparin.                            These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
                  <action>
                    <title value="Select one or both."/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate. If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate. If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="Acute Pulmonary Embolism"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux,                             subcutaneous unfractionated heparin,                            intravenous heparin.                            These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
                  <action>
                    <title value="Select one or both."/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.  If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.  If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="High Clinical Suspicion of Acute Pulmonary Embolism"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux,                             subcutaneous unfractionated heparin,                            intravenous heparin.                            These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
                  <action>
                    <title value="Select one or both."/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="Intermediate Clinical Suspicion of Acute Pulmonary Embolism if Results of Diagnostic Tests Expected to Be Delayed >4 Hours"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux,                             subcutaneous unfractionated heparin,                            intravenous heparin.                            These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
                  <action>
                    <title value="Select one or both."/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now."/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now."/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="Acute Pulmonary Embolism and Inferior Vena Cava Filter if Risk of Bleeding Resolves"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux,                             subcutaneous unfractionated heparin,                            intravenous heparin.                            These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
                  <action>
                    <title value="Select one or both."/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                               If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours. If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                               If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="Asymptomatic Pulmonary Embolism"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux,                             subcutaneous unfractionated heparin,                            intravenous heparin.                            These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
                  <action>
                    <title value="Select one or both."/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.                                               If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol: If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.                                               If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="Acute Upper-Extremity Deep Vein Thrombosis that Involves Axillary or More Proximal Veins"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux,                             subcutaneous unfractionated heparin,                            intravenous heparin.                            These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
                  <action>
                    <title value="Select one or both."/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol:                                               If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.                                               If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol:                                               If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.                                               If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="Acute Upper-Extremity Deep Vein Thrombosis with Thrombolysis"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux, subcutaneous unfractionated heparin, intravenous heparin. These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
                  <action>
                    <title value="Select one or both"/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol:                                               If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.                                               If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                               If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol:                                               If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.                                               If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                               If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="Symptomatic Splanchnic Vein Thrombosis"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux, subcutaneous unfractionated heparin, intravenous heparin. These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
                  <action>
                    <title value="Select one or both"/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol:                                               If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.                                               If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                               If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol:                                               If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.                                               If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                               If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="Symptomatic Hepatic Vein Thrombosis"/>
                <description value="Be advised that the patient is a candidate for intravenous unfractionated heparin, although other options may be preferred based on individual patient characteristics, clinical co-conditions or co-morbidities, and patient values and preferences.  The medication treatment options for this patient subpopulation include the following, but the options cannot be strictly rank-ordered in terms of a universal preference, and individual patient circumstances must be considered in selecting the optimal treatment:                             dalteparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            enoxaparin (a drug of choice in patients with cancer and in patients with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or edoxaban),                            fondaparinux,subcutaneous unfractionated heparin, intravenous heparin. These are links to the American College of Chest Physicians VTE treatment guidelines:"/>
                <action>
                  <title value="Dalteparin orders"/>
                  <action>
                    <title value="For patients with body weight equal or less than 56 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 10,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 57-68 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 12,500 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 69-82 kg"/>
                    <action>
                      <title/>
                      <description value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 15,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 82 kg."/>
                    <action>
                      <title/>
                      <description value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Dalteparin 18,000 IU solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Weight-based Enoxaparin"/>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1 mg/kg subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                  <action>
                    <title/>
                    <description value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    <definitionCanonical>
                      <display value="Enoxaparin 1.5 mg/kg subcutaneous every 24 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Fondaparinux orders"/>
                  <action>
                    <title value="For patients with body weight less than 50 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight 50-100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 7.5 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title value="For patients with body weight greater than 100 kg"/>
                    <action>
                      <title/>
                      <description value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      <definitionCanonical>
                        <display value="Fondaparinux 10 mg solution subcutaneous, daily"/>
                      </definitionCanonical>
                    </action>
                  </action>
                </action>
                <action>
                  <title value="Subcutaneous unfractionated heparin"/>
                  <action>
                    <title/>
                    <description value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    <definitionCanonical>
                      <display value="Unfractionated heparin 15,000 U solution subcutaneous every 12 hours"/>
                    </definitionCanonical>
                  </action>
                </action>
                <action>
                  <title value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
                  <action>
                    <title value="Select one or both"/>
                    <selectionBehavior value="at-most-one"/>
                    <action>
                      <title/>
                      <description value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      <definitionCanonical>
                        <display value="Heparin 80 U/kg body weight intravenous solution 1 time bolus now"/>
                      </definitionCanonical>
                    </action>
                    <action>
                      <title value="TSR-NoCode"/>
                      <description value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol:                                               If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.                                               If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                               If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      <definitionCanonical>
                        <display value="Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab 6 hours after initiating heparin infusion, and for any aPTT lab result titrate heparin IV infusion per the following protocol:                                               If aPTT is less than 35 sec, give 80 U/kg heparin bolus, then increase heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                                If aPTT 46-70 sec, no change in heparin infusion rate.   If both the current and the previous aPTT value are equal or greater than 46 and equal to or less than 70, then draw the next aPTT lab with the next morning lab draw.  Otherwise, draw aPTT lab in 6 hours.                                               If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change.                                               If aPTT is greater than 90 sec, hold the heparin infusion for 1 hour, then decrease heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change."/>
                      </definitionCanonical>
                    </action>
                  </action>
                  <action>
                    <title/>
                    <description value="IV Heparin Infusion"/>
                    <definitionCanonical>
                      <display value="IV Heparin Infusion"/>
                    </definitionCanonical>
                  </action>
                </action>
              </action>
            </action>
            <action>
              <title value="Perioperative Anticoagulation with Mechanical Heart Valve, Atrial Fibrillation or Venous Thromboembolism at High Risk for additional (perioperative) Thromboembolism"/>
              <selectionBehavior value="at-most-one"/>
            </action>
            <action>
              <title value="Perioperative Anticoagulation with Unfractionated Heparin Timing of Pre-surgical Stopping of Unfractionated Heparin"/>
              <selectionBehavior value="at-most-one"/>
            </action>
            <action>
              <title value="Pregnancy with Antiphospholipid Antibody Syndrome"/>
              <selectionBehavior value="at-most-one"/>
            </action>
            <action>
              <title value="Pregnancy with Mechanical Heart Valve"/>
              <selectionBehavior value="at-most-one"/>
            </action>
          </action>
          <action>
            <title value="Laboratory Tests"/>
            <action>
              <selectionBehavior value="at-most-one"/>
              <action>
                <title value="26604007 |Complete blood count (procedure)|"/>
                <description value="Complete blood count 1 time now"/>
                <definitionCanonical>
                  <display value="Complete blood count 1 time now"/>
                </definitionCanonical>
              </action>
              <action>
                <title value="26604007 |Complete blood count (procedure)|"/>
                <description value="Complete blood count 1 time in the morning"/>
                <definitionCanonical>
                  <display value="Complete blood count 1 time in the morning"/>
                </definitionCanonical>
              </action>
              <action>
                <title value="1421000205106 |Basic metabolic panel (procedure)"/>
                <description value="Basic metabolic profile 1 time now"/>
                <definitionCanonical>
                  <display value="Basic metabolic profile 1 time now"/>
                </definitionCanonical>
              </action>
              <action>
                <title value="1421000205106 |Basic metabolic panel (procedure)"/>
                <description value="Basic metabolic profile 1 time in the morning"/>
                <definitionCanonical>
                  <display value="Basic metabolic profile 1 time in the morning"/>
                </definitionCanonical>
              </action>
              <action>
                <title value="42525009 |Partial thromboplastin time, activated (procedure)|"/>
                <description value="Activated partial thromboplastin time every 6 hours routine"/>
                <definitionCanonical>
                  <display value="Activated partial thromboplastin time every 6 hours routine"/>
                </definitionCanonical>
              </action>
              <action>
                <title value="440685005 |Calculation of international normalized ratio (procedure)|"/>
                <description value="International normalized ratio daily 1 time routine"/>
                <definitionCanonical>
                  <display value="International normalized ratio daily 1 time routine"/>
                </definitionCanonical>
              </action>
            </action>
          </action>
        </action>
      </PlanDefinition>
    </resource>
    <request>
      <method value="POST"/>
    </request>
  </entry>
  <entry>
    <resource>
      <Questionnaire>
        <title value="Medications"/>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="Acute DVT of Leg Treated with Vitamin K Antagonist"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg."/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg."/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg."/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg."/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg."/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg."/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg."/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion:"/>
              <item>
                <text value="Select one or both."/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="High Clinical Suspicion of Acute VTE"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg."/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg."/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg."/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg."/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg."/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion:"/>
              <item>
                <text value="Select one or both."/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="Intermediate Clinical Suspicion of Acute VTE and Results of Diagnostic Tests Expect to Be Delayed > 4 Hours"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg."/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg."/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg."/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg."/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg."/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg"/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion:"/>
              <item>
                <text value="Select one or both."/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="Acute Isolated Distal DVT of Leg and Severe Symptoms or Risk Factors for Extension"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg"/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg"/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
              <item>
                <text value="Select one or both"/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="Acute Isolated Distal DVT of Leg if Thrombus Extends within Distal System or into Proximal Veins"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg"/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg"/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
              <item>
                <text value="Select one or both."/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="Acute Deep Vein Thrombosis of Leg with Thrombosis Removal"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg"/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg"/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion:"/>
              <item>
                <text value="Select one or both."/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="Acute Proximal Deep Vein Thrombosis of Leg and Inferior Vena Cava Filter if Risk of Bleeding Resolves"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg"/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg"/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
              <item>
                <text value="Select one or both."/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="Acute Pulmonary Embolism"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg"/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg"/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
              <item>
                <text value="Select one or both."/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="High Clinical Suspicion of Acute Pulmonary Embolism"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg"/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg"/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
              <item>
                <text value="Select one or both."/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="Intermediate Clinical Suspicion of Acute Pulmonary Embolism if Results of Diagnostic Tests Expected to Be Delayed >4 Hours"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg"/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg"/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
              <item>
                <text value="Select one or both."/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="Acute Pulmonary Embolism and Inferior Vena Cava Filter if Risk of Bleeding Resolves"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg"/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg"/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
              <item>
                <text value="Select one or both."/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="Asymptomatic Pulmonary Embolism"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg"/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg"/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
              <item>
                <text value="Select one or both."/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="Acute Upper-Extremity Deep Vein Thrombosis that Involves Axillary or More Proximal Veins"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg"/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg"/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
              <item>
                <text value="Select one or both."/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="Acute Upper-Extremity Deep Vein Thrombosis with Thrombolysis"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg"/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg"/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
              <item>
                <text value="Select one or both"/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="Symptomatic Splanchnic Vein Thrombosis"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg"/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg"/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
              <item>
                <text value="Select one or both"/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text/>
          <type value="choice"/>
          <item>
            <text value="Symptomatic Hepatic Vein Thrombosis"/>
            <item>
              <text value="Dalteparin orders"/>
              <item>
                <text value="For patients with body weight equal or less than 56 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 57-68 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 69-82 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 82 kg."/>
              </item>
            </item>
            <item>
              <text value="Weight-based Enoxaparin"/>
            </item>
            <item>
              <text value="Fondaparinux orders"/>
              <item>
                <text value="For patients with body weight less than 50 kg"/>
              </item>
              <item>
                <text value="For patients with body weight 50-100 kg"/>
              </item>
              <item>
                <text value="For patients with body weight greater than 100 kg"/>
              </item>
            </item>
            <item>
              <text value="Subcutaneous unfractionated heparin"/>
            </item>
            <item>
              <text value="Orders for Initiation and Maintenance of IV Heparin infusion"/>
              <item>
                <text value="Select one or both"/>
                <type value="choice"/>
              </item>
            </item>
          </item>
        </item>
        <item>
          <text value="Perioperative Anticoagulation with Mechanical Heart Valve, Atrial Fibrillation or Venous Thromboembolism at High Risk for additional (perioperative) Thromboembolism"/>
          <type value="choice"/>
        </item>
        <item>
          <text value="Perioperative Anticoagulation with Unfractionated Heparin Timing of Pre-surgical Stopping of Unfractionated Heparin"/>
          <type value="choice"/>
        </item>
        <item>
          <text value="Pregnancy with Antiphospholipid Antibody Syndrome"/>
          <type value="choice"/>
        </item>
        <item>
          <text value="Pregnancy with Mechanical Heart Valve"/>
          <type value="choice"/>
        </item>
      </Questionnaire>
    </resource>
    <request>
      <method value="POST"/>
    </request>
  </entry>
  <entry>
    <resource>
      <Questionnaire>
        <title value="Laboratory Tests"/>
        <item>
          <text/>
          <type value="choice"/>
        </item>
      </Questionnaire>
    </resource>
    <request>
      <method value="POST"/>
    </request>
  </entry>
</Bundle>
